Realistic patterns: Months 1-2: 3-8 pounds (as dose increases) Months 3-6: 4-8 pounds per month at higher doses Months 7-12: 2-4 pounds per month (tapering is normal) Individual variation is massive
The effectiveness of Semaglutide GLP-1 can vary depending on factors such as starting weight, lifestyle, and other medications
Clinicians have also noted that sudden caloric deficits can lead the brain to decrease reproductive hormone production as a protective mechanism
However, over time, the effect on appetite decreased even though the weight loss continued
Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic injection in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic injection 0.5 mg + basal insulin MET 10.7% with Ozempic injection 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic injection in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 Adverse events 5% in SUSTAIN FORTE 4 AEs occurring in 5% of patients receiving Ozempic injection 1 mg and 2 mg in SUSTAIN FORTE In placebo-controlled trials, the most common adverse reactions reported in 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation 1 No new safety signals were identified
